Effect of lisinopril and perindopril on serum lipid profile in Albino rabbits

Shruti Chandra, S. P. Singh, Rashmi Singh, Neeraj Kumar Agarwal


Background: Hypertension with dislipidemia is becoming a common morbidity, since ACE inhibitors are the first line of antihypertensive drugs so present study was undertaken with the aim to evaluate the possible effects of ACE inhibitor on lipid profile in albino rabbits.

Methods: The study was conducted in the Department of Pharmacology and Therapeutics, GSVM Medical College, Kanpur. Rabbits were divided into 2 groups with 6 in each group. Rabbits of Group I was given Lisinopril in dose of 0.25mg/kg and of group II was given Perindopril in dose of 0.20mg/kg for a period of 6 weeks. Lipid profile estimation (Serum Total cholesterol, serum HDL, serum LDL, serum Triglycerides and serum VLDL) was done at day 0, 7, 21 and 45 respectively.

Results: After analysis Rabbits of group-I (Lisinopril) showed 3.1% decrease in serum cholesterol level at 45th day (P<0.001). Serum HDL level increased by 6.4% and 14.3% at day 21 and 45 respectively (P<0.05). Increase in serum Triglyceride level was 2.6% at day 45 (P>0.05). Serum LDL level decreases by 4.4% and 8.6% at day 21 and 45 respectively (P<0.001). There was no significant change in Serum VLDL level. Rabbits of group- II (Perindopril) showed decreased total cholesterol levels by 2.6% (P<0.05). There was an increase in HDL level by 6.8 % at day 45(P<.05). Triglycerides and VLDL levels were not significantly altered while serum LDL level decreases by 6.7% at day 45 (P<0.01).

Conclusions: From our study it was concluded that Lisinopril had a favourable effect on serum lipid profile by decreasing total cholesterol, increasing serum HDL level. It may increase triglycerides, decrease LDL. Perindopril increase serum HDL and decreases LDL, there is no significant change in cholesterol, TG and VLDL levels.


ACE inhibitors, serum lipid profile, albino rabbits

Full Text:



Dodu SR. Coronary heart disease in developing countries: the threat can be averted. WHO Chron. 1984;38:3-7.

Akinkugbe OO. Epidemiology of cardiovascular disease in developing countries. J. Hypertens. 1990;8:233-8.

Park K. Cardiovascular diseases: problem statement. Epidemiology of chronic noncommunicable diseases and conditions. Park’s Text Book of Preventive and Social Medicine. 20th Ed; 2009:315-316.

Park K. Coronary heart diseases. Park’s Text Book of Preventive and Social Medicine. 20th Ed; 2009:317- 3181.

Libby P. Prevention and treatment of Atherosclerosis. Braunwald E, Frauci S, Kasper DL, Hauser SL, Lango DL, et al. Harrison’s Principles of Internal Medicine. 16th Ed. Mc Graw-Hill; 2005:1424-1430.

Sloop GD, Williams KJ, Tabas I, Weissberg PL, Bennett MR, Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med. 1999;340:1928-9.

Libby P. Prevention and treatment of Atherosclerosis. Braunwald E, Frauci S, Kasper DL, Hauser SL, Lango DL, et al. Harrison’s Principles of Internal Medicine. 15th Ed. Mc Graw-Hill; 2005:1382-1430.

Boon N, Fox K, Bloomfield P, Bradburry A. Coronary artery disease. Haslet C, Chilvers E, Colledge N. Davidson Principles and Practice of Medicine.19th Ed: Churchill Livingstone; 2004:424.

Itsik BD, Alexander B. Treatment of stable angina, Coronary heart disease. Heart. 2007;93:868-74.

Hoffman BB. Treatment of myocardial ischemia and Hypertension. Bruton LL, Lazo JS and Parker KL. Goodman and Gilman The Pharmacological Basis of Therapeutics, 12th ed: Mc Graw-Hill; 2005:772-778.

Theodore A. hypertensive vascular disease. Braunwald E, Frauci S, Kasper DL, Hauser SL, Lango DL, Jameson JL. Harrison’s Principles Of Internal Medicine, 17th Ed: Mc Graw-Hill; 2008:1559-1562.

Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful marriage? Cur Med Res Opin. 2004;20(3):359-67.

Christian Weber and Oliver Soehnlei. ApoE controls the interface linking lipids and inflammation in atherosclerosis J Clin Invest. 2011;121(10):3825-7.

Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Effects of fosinopril on blood pressure, lipid profile, and lipoprotein(a) levels in normotensive patients with type II diabetes and microalbuminuria, An open-label, uncontrolled study. Current therapeutic research. 2002;63(3):216-26.

Pagets GE, Barnes JM. Pharmacometrics. In: Laurence D.R., Bacharach A.L. editors. Evaluation of drug activities. 1st Ed. New York and London: Academic press; 1964.

Anichkov AD, Shostak AN, Schastnaya. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Current medical research and opinion. 2005;21(1):113-9.

Ruggenenti P, Mise N, Pisoni R, Arnoldi F, Pezzotta A, Perna A, et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation. 2003 Feb 4;107(4):586-92.

Fogari R, Zoppi A, Malamani GD, Marasi G, Vanasia A, Villa G. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol. 1995;39(5):471-6.

Williams LL, Lopez LM, Thorman AD, Quay GP, Stein GH, Mehta JL. Plasma lipid profiles and antihypertensive agents: effects of lisinopril, enalapril, nitrendipine, hydralazine, and hydrochlorothiazide. Drug Intell Clin Pharm 1988;22(7-8):546-50.

Bezrodna L, Svyshchenko Y, Bezrodnyy V, Mishchenko L. Effects of Ace Inhibitor Perindopril And Calcium Antagonist Lercanidipine On Lipids Profile In Hypertensive Patients With Chronic Kidney Disease: Pp. 23.451. J of Hypertension. 2010 Jun 1;28:e380.

Bak JF, Gerdes LU, Sørensen NS, Pedersen O. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. The American journal of medicine. 1992 Apr 27;92(4):S69-72.

Rang PH, Dale MM, Ritter MJ. the vascular system. Rang and Dale Pharmacology, 6th Ed: Churchill livingstone; 2007:304.

Botham MK, Mayes AP. Lipid transport and storage. Murray KR, Granner KD, Rodwell WV. Harper’s illustrated biochemistry, 27th Ed: Mc graw hill; 2006:227.

Champe PC, Harvey RA, Ferrier DR. Fatty acid and triacylglycerol metabolism. Lippincott’s Illustrated Review Biochemistry, 4th Ed: Lippincott William and Wikkin; 2008:190.

Ganong WF. Endocrine functions of pancreas and regulation of carbohydrate metabolism. Review of medical physiology, 22nd Ed: Mc graw hill; 2005:337.

Champe PC, Harvey RA, Ferrier DR. Cholesterol and steroid metabolism. Lippincott’s Illustrated Review Biochemistry, 4th Ed: Lippincott William and Wikkin; 2008:223.

Lu H, Boustany-Kari CM, Daugherty A, Cassis LA. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab. 2007;292:E1280-E1290.

Goossens GH, Blaak EE, Arner P, Saris WH, Baak MA. Angiotensin II: a hormone that affects lipid metabolism in adipose tissue. Int J Obesity. 2007;31:382-4.

Huang ZH, Reardon CA, Mazzone T. Endogenous apoE expression modulates adipocyte triglyceride content and turnover. Diabetes. 2006;55:3394-402.

Rao P, Huang ZH, Mazzone T. Angiotensin II regulates adipocyte apolipoprotein E expression. The J of Cli Endo & Metabo. 2007 Nov 1;92(11):4366-72.